Sun BioPharma, a biopharmaceutical company developing therapies for the treatment of pancreatic cancer, has appointed David Kaysen as President and Chief Executive. He has also joined the company's board of directors.
Kaysen brings to Sun BioPharma more than 25 years of healthcare clinical development, commercial and public company achievements. He joins the company as its lead development candidate, SBP-101, is expected to begin a Phase 1 clinical trial in Australia by the end of this year for the treatment of pancreatic cancer.
Prior to joining Sun, Kaysen was an advisor and senior executive to several domestic and European privately held healthcare companies. From 2006 to 2013 he was President and Chief Executive of Uroplasty, a global medical device company that is now part of Cogentix Medical. Before this he was President and CEO of Advanced Duplications Services; President, Chief Executive and a director of Diametrics Medical and President, Chief Executive and a director of Rehabilicare.
